淋巴细胞与单核细胞比值与恶性肿瘤预后的关系

doi:10.3760/cma.j.issn.1673-422X.2016.10.011

摘要/Abstract

摘要： 相关研究已经证实，肿瘤相关炎症与多种肿瘤的进展及预后相关。作为一种炎症生物标志物，淋巴细胞与单核细胞比值在预测恶性肿瘤预后中显示出重要的应用价值。它不仅可以对肿瘤患者进行恰当的风险分层，还可以给后续个体化治疗方案的制定提供依据。

关键词: 淋巴细胞, 单核细胞, 肿瘤, 预后

Abstract: Related studies have been confirmed that tumorassociated inflammation is associated with tumor progression and prognosis in a variety of tumors. As an inflammatory biomarker, lymphocytemonocyte ratio shows significant value in predicting the prognosis of malignant tumors. It can not only be appropriate for patients with cancer risk stratification, but also provide the basis for the subsequent development of individualized treatment programs.

Key words: Lymphocytes, Monocytes, Neoplasms, Prognosis

钱门龙,卢宁. 淋巴细胞与单核细胞比值与恶性肿瘤预后的关系[J]. 国际肿瘤学杂志, 2016, 43(10): 769-771.

Qian Menlong, Lu Ning. Relationship between lymphocytemonocyte ratio and prognosis of malignant tumors[J]. Journal of International Oncology, 2016, 43(10): 769-771.

参考文献

［1］ Landskron G, De la Fuente M, Thuwajit P, et a1. Chronic inflammation and cytokines in the tumor microenvironment［J］. J Immunol Res, 2014, 2014: 149185. DOI: 10.1155/2014/149185. ［2］ Zhang J, Huang SH, Li H, et a1. Preoperative lymphocyte count is a favorable prognostic factor of diseasefree survival in nonsmallcell lung cancer［J］. Med Oncol, 2013, 30(1): 352. DOI: 10.1007/s1203201203523. ［3］ Botta C, Barbieri V, Ciliberto D, et a1. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced nonsmall cell lung cancer patients［J］. Cancer Biol Ther, 2013, 14(6): 469-475. DOI: 10.4161/cbt.24425. ［4］ Li J, Jiang R, Liu WS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocytetomonocyte ratio with favorable prognosis in nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(12): e83069. DOI: 10.1371/journal.pone.0083069. ［5］ Li YL, Pan YY, Jiao Y, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard firstline regimens［J］. Ann Hematol, 2014, 93(4): 617-626. DOI: 10.1007/s0027701319169. ［6］ Jiang R, Cai XY, Yang ZH, et al. Elevated peripheral blood lymphocytetomonocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma［J］. Chin J Cancer, 2015, 34(6): 237-246. DOI: 10.1186/s4088001500257. ［7］ Lin GN, Peng JW, Xiao JJ, et al. Prognostic impact of circulating monocytes and lymphocytetomonocyte ratio on previously untreated metastatic nonsmall cell lung cancer patients receiving platinumbased doublet［J］. Med Oncol, 2014, 31(7): 70. DOI: 10.1007/s1203201400700. ［8］ Hu P, Shen H, Wang G, et al. Prognostic significance of systemic inflammationbased lymphocytemonocyte ratio in patients with lung cancer: based on a large cohort study［J］. PLoS One, 2014, 9(9): e108062. DOI: 10.1371/journal.pone.0108062. ［9］ Go SI, Kim RB, Song HN, et al. Prognostic significance of the lymphocytetomonocyte ratio in patients with small cell lung cancer［J］. Med Oncol, 2014, 31(12): 323. DOI: 10.1007/s120320140323y. ［10］ Chen YM, Lai CH, Chang HC, et al. Baseline and trend of lymphocytetomonocyte ratio as prognostic factors in epidermal growth factor receptor mutant nonsmall cell lung cancer patients treated with firstline epidermal growth factor receptor tyrosine kinase inhibitors［J］. PLoS One, 2015, 10(8): e0136252. DOI: 10.1371/journal.pone.0136252. ［11］ Amedei A, Benagiano M, della Bella C, et al. Novel immunotherapeutic strategies of gastric cancer treatment［J］. J Biomed Biotechnol, 2011, 2011: 437348. DOI: 10.1155/2011/437348. ［12］ Zhou X, Du Y, Xu J, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage Ⅱ/Ⅲ gastric cancer［J］. Tumour Biol, 2014, 35(11): 11659-11666. DOI: 10.1007/s132770142504x. ［13］ Deng Q, He B, Liu X, et al. Prognostic value of preoperative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model［J］. J Transl Med, 2015, 13: 66. DOI: 10.1186/s1296701504090. ［14］ Ozawa T, Ishihara S, Kawai K, et al. Impact of a lymphocyte to monocyte ratio in stage Ⅳ colorectal cancer［J］. J Surg Res, 2015, 199(2): 386-392. DOI: 10.1016/j.jss.2015.06.014. ［15］ Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage Ⅲ colon cancer［J］. Br J Cancer, 2014, 110(2): 435-440. DOI: 10.1038/bjc.2013.785. ［16］ Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscleinvasive and metastatic bladder cancer: summary of the 2013 guidelines［J］. Eur Urol, 2014, 65(4): 778-792. DOI: 10.1016/j.eururo.2013.11.046. ［17］ Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase Ⅲ study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscleinvasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209［J］. Ann Oncol, 2014, 25(6): 1192-1198. DOI: 10.1093/annonc/mdu126. ［18］ Temraz S, Mukherji D, Farhat ZA, et al. Preoperative lymphocytetomonocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis［J］. BMC Urol, 2014, 14: 76. DOI: 10.1186/147124901476. ［19］ Yoshida T, Kinoshita H, Yoshida K, et al. A novel risk stratification model, involving preoperative lymphocytemonocyte ratio and standard pathological factors, for overall survival in patients with bladder cancer undergoing radical cystectomy［J］. Jpn J Clin Oncol, 2015, 45(12): 1162-1167. DOI: 10.1093/jjco/hyv146.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.